Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tris Pharma has received US Food and Drug Administration's (FDA) acceptance of its extended release Carbinoxamine Oral Suspension NDA to treat allergies in kids of two years and older.
Subscribe to our email newsletter
Tris Pharma said if the drug will be approved by the FDA its extended release suspension will offer an alternative to the currently available immediate release formulations.
The company is planning to launch Carbinoxamine extended release suspension in 2012 season and is currently evaluating its options including partnering with other specialty Pharma companies.
Tris Pharma president and CEO Ketan Mehta said this is the fourth NDA submission based on Tris’ OralXR+ technology platform including Nexiclon XR, a recently launched first ever 24-hour liquid Extended Release Suspension.